Shi‐Ming Lin

4.1k citations

62 papers · 2.7k indexed · 1 hit paper · h-index 22

Hepatology top 0.2%
Epidemiology top 2%
Surgery top 10%
Oncology top 10%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Chen‐Chun Lin Yi‐Cheng Chen I‐Shyan Sheen Chao‐Wei Hsu Chun‐Jung Lin Yun‐Fan Liaw Deng‐Yn Lin Wei‐Ting Chen
Topics: Liver Disease Diagnosis and Treatment (38 papers)Hepatocellular Carcinoma Treatment and Prognosis (36 papers)Hepatitis B Virus Studies (17 papers)
Cited by: Hepatology Epidemiology Cancer Research
Journals: Journal of Clinical Oncology Gastroenterology PLoS ONE
Partner nations: Taiwan United States China

In The Last Decade

Shi‐Ming Lin

59 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

2024 93 citations Shi‐Ming Lin et al. profile →

Peers

Countries citing papers authored by Shi‐Ming Lin

Since Specialization

Citations

This map shows the geographic impact of Shi‐Ming Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Ming Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Ming Lin more than expected).

Fields of papers citing papers by Shi‐Ming Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐Ming Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Ming Lin. The network helps show where Shi‐Ming Lin may publish in the future.

Co-authorship network of co-authors of Shi‐Ming Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐Ming Lin. A scholar is included among the top collaborators of Shi‐Ming Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐Ming Lin. Shi‐Ming Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation 2025 ·Liver Cancer ·Ming‐Shun Wu,Wei‐Yu Kao,(unknown),(unknown),Shih–Jer Hsu,Shen-Yung Wang,(unknown),Chen‐Chun Lin,Chao‐Hung Hung,Chih‐Horng Wu,San‐Chi Chen,Hsin‐Lun Lee,Jen-I Hwang,Po‐Chin Liang,Shi‐Ming Lin,(unknown)	0
2	Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients 2025 ·Journal of Hepatocellular Carcinoma ·(unknown),(unknown),Wei Teng,Jenhui Chen,(unknown),(unknown),Chen‐Chun Lin,Chun‐Yen Lin,Shi‐Ming Lin	0
3	Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma 2024 ·The Oncologist ·(unknown),Wei Teng,Eric Yi-Liang Shen,Bing‐Shen Huang,(unknown),Ming‐Mo Hou,Tsung‐Han Wu,Din‐Li Tsan,Chia‐Hsun Hsieh,(unknown),(unknown),Chun‐Yen Lin,Shi‐Ming Lin,Chen‐Chun Lin	6
4	A Primary Extraskeletal Osteosarcoma of the Spleen: Rare Case Report 2022 ·Frontiers in Oncology ·Xian Pan,Hanlu Wang,Shi‐Ming Lin,(unknown),Dan‐dan Ruan,Jianhui Zhang,Ting Chen,Jie-wei Luo,Zhu-ting Fang	1
5	A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness 2021 ·PLoS ONE ·(unknown),Chien‐Ming Chen,Bing‐Shen Huang,(unknown),Kuang‐Tse Pan,Shi‐Ming Lin,Sung‐Yu Chu,Jeng‐Hwei Tseng	2
6	Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients 2020 ·Advances in digestive medicine ·(unknown),Wei Teng,(unknown),Wen‐Juei Jeng,Chien‐Hao Huang,Kar‐Wai Lui,(unknown),Yi‐Cheng Chen,Chen‐Chun Lin,(unknown),Chun‐Yen Lin,Shi‐Ming Lin,I‐Shyan Sheen	2
7	Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study 2019 ·Journal of International Medical Research ·(unknown),(unknown),Chao‐Wei Lee,Tsung‐Han Wu,(unknown),Shi‐Ming Lin,Ming‐Chin Yu,Chien‐Fu Hung	1
8	Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment 2014 ·Digestive Diseases ·Wen‐Juei Jeng,Chen‐Chun Lin,Wei‐Ting Chen,I‐Shyan Sheen,Chun‐Yen Lin,Shi‐Ming Lin	14
9	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma 2014 ·PLoS ONE ·(unknown),(unknown),Ya‐Hui Chuang,Yahui Wang,(unknown),Chih‐Feng Wu,Chih‐Lin Lin,Chun‐Jen Liu,Yun‐Fan Liaw,Shi‐Ming Lin,Pei‐Jer Chen,Shou‐Dong Lee,Ming‐Whei Yu	60
10	Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients 2014 ·Biomedical Journal ·Chao‐Wei Hsu,(unknown),Chau‐Ting Yeh,Shi‐Ming Lin,Cheng‐Tang Chiu,(unknown)	9
11	High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities 2013 ·Oncology Letters ·(unknown),Ngan‐Ming Tsang,Shi‐Ming Lin,Deng‐Yn Lin,Jau‐Min Lien,(unknown),Wei‐Ting Chen,Chen Wy,Ji-Hong Hong	9
12	Local Ablation for Hepatocellular Carcinoma in Taiwan: Different Points between Japan, Asia and West 2010 ·Oncology ·Shi‐Ming Lin	4
13	Delay in treatment of early‐stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program 2010 ·Journal of Surgical Oncology ·Wei‐Ting Chen,(unknown),Chen‐Chun Lin,Shi‐Ming Lin	20
14	Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time† 2009 ·Hepatology ·Dar‐In Tai,Shi‐Ming Lin,I‐Shyan Sheen,Chia‐Ming Chu,Deng‐Yn Lin,Yun‐Fan Liaw	135
15	Treatment of Hepatocellular Carcinoma Using Internally Cooled Electrodes 2007 ·Oncology ·(unknown),Chen‐Chun Lin,Chun‐Jung Lin,Wei‐Ting Chen,Chao‐Wei Hsu,Yi‐Cheng Chen,Stephen N. Wong,Shi‐Ming Lin	7
16	Fine‐needle aspiration cytology to distinguish dysplasia from hepatocellular carcinoma with different grades 2007 ·Journal of Gastroenterology and Hepatology ·Chen‐Chun Lin,Chun‐Jung Lin,Chao‐Wei Hsu,Yi‐Cheng Chen,Wei‐Ting Chen,Shi‐Ming Lin	10
17	Radiofrequency Ablation for Hepatocellular Carcinoma: A Prospective Comparison of Four Radiofrequency Devices 2007 ·Journal of Vascular and Interventional Radiology ·Shi‐Ming Lin,Chen‐Chun Lin,Wei‐Ting Chen,Yi‐Chen Chen,Chao‐Wei Hsu	28
18	A Novel Ex Vivo Assay of Interferon‐Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C 2006 ·The Journal of Infectious Diseases ·Chau‐Ting Yeh,Chao‐Wei Hsu,Ming‐Ling Chang,I‐Shyan Sheen,Shi‐Ming Lin,Chun‐Jung Lin,Chen‐Chun Lin,Yi‐Cheng Chen,Jeng‐Chang Chen	3
19	Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm 2004 ·Gastroenterology ·Shi‐Ming Lin,Chun‐Jung Lin,Chen‐Chun Lin,Chao‐Wei Hsu,Yi‐Cheng Chen	439
20	Response of Patients with Dual Hepatitis B Virus and C Virus Infection to Interferon Therapy 1997 ·Journal of Interferon & Cytokine Research ·Yun‐Fan Liaw,Rong‐Nan Chien,Shi‐Ming Lin,Chau‐Ting Yeh,Sun‐Lung Tsai,I‐Shyan Sheen,(unknown)	46

About Shi‐Ming Lin

Shi‐Ming Lin is a scholar working on Hepatology, Epidemiology and Cancer Research, having authored 62 papers that have together received 2.7k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (36 papers) and Hepatitis B Virus Studies (17 papers). The work is most often cited by research in Hepatology (2.0k citations), Epidemiology (1.6k citations) and Cancer Research (238 citations). Shi‐Ming Lin has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Chen‐Chun Lin, Yi‐Cheng Chen, I‐Shyan Sheen, Chao‐Wei Hsu, Chun‐Jung Lin, Yun‐Fan Liaw, Deng‐Yn Lin, Wei‐Ting Chen, Chun‐Jen Liu and Chuan–Mo Lee. Their work appears in journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact